Heart failure & cardiomyopathies
Quality of life and societal costs in patients with dilated cardiomyopathy
Authors' conclusion
DCM is associated with high societal costs and reduced QoL, in particular with high DCM severity.
Study context
- Population
- Patients with dilated cardiomyopathy (DCM); mean age 61 years, 34% women
- Participants
- 550 patients
- Exposure
- NYHA class III or IV vs less symptomatic DCM
- Outcome
- Quality of life (QoL) (EQ-5D-5L utilities) and societal costs (Dutch societal perspective, 2022 Euros)
- Follow-up
- Extrapolated to 1 year
Methodological detailsMaastricht cardiomyopathy registry
- Maastricht cardiomyopathy registry
Main finding
As reported in the abstract
QoL and societal costs · per year
| Group | Average DCM costs per year | Utility |
|---|---|---|
| NYHA III–IV | €31 099 | 0.631 |
| Less symptomatic DCM | €11 446 | 0.883 |
Average DCM costs per year
NYHA III–IV€31 099
Less symptomatic DCM€11 446
Utility
NYHA III–IV0.631
Less symptomatic DCM0.883
- NYHA III–IV vs Less symptomatic DCM: P < 0.001 — costs
- NYHA III–IV vs Less symptomatic DCM: P < 0.001 — utilities
- Total societal DCM costs per patient per year
- €14 843
- Productivity losses
- €7037
- Medical costs
- €4621
- Overall utility, DCM vs population mean
- 0.840 vs. 0.869, P = 0.225
Observational data: associations, not effects.
Original publication
Quality of life and societal costs in patients with dilated cardiomyopathy. Eur Heart J Qual Care Clin Outcomes. Published 14 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it